Suppr超能文献

利用溶剂暴露的盐桥相互作用,通过自由能微扰模拟发现SOS1的强效抑制剂。

Exploiting Solvent Exposed Salt-Bridge Interactions for the Discovery of Potent Inhibitors of SOS1 Using Free-Energy Perturbation Simulations.

作者信息

Leffler Abba E, Houang Evelyne M, Gray Felicia, Placzek Andrew T, Ruvinsky Anatoly M, Bell Jeffrey A, Wang Hui, Sun Shaoxian, Svensson Mats, Greenwood Jeremy R, Frye Leah L, Igawa Hideyuki, Atsriku Christian, Levinson Adam M

机构信息

Schrödinger, Inc., New York, New York 10036, United States.

Schrödinger, Inc., Portland, Oregon 97204, United States.

出版信息

ACS Med Chem Lett. 2025 Feb 28;16(3):444-453. doi: 10.1021/acsmedchemlett.4c00602. eCollection 2025 Mar 13.

Abstract

Small molecules that bind the Son of Sevenless 1 protein (SOS1), thereby preventing activation of RAS, have been widely pursued as a means for cell proliferation inhibition and antitumor activity. Guided by free-energy perturbation (FEP+) simulations, we discovered that two acidic residues on the perimeter of a known small molecule binding site on SOS1, E906 and E909, constitute a potency handle that can improve inhibitor affinity by as much as 750-fold when targeted with basic groups to form salt bridges, despite being solvent exposed. Structure-Activity Relationship (SAR) and X-ray crystallographic studies demonstrate that this effect is attributable to the electrostatic interaction between the protein and ligand. This interaction could be repurposed to create new SOS1 inhibitors, documenting its general utility for core exploration. Additional recent examples in the literature suggest that this phenomenon may be applicable to a number of target classes and are highlighted herein.

摘要

与七号less之子1蛋白(SOS1)结合从而阻止RAS激活的小分子,已被广泛研究作为抑制细胞增殖和抗肿瘤活性的一种手段。在自由能微扰(FEP+)模拟的指导下,我们发现SOS1上一个已知小分子结合位点周边的两个酸性残基E906和E909,构成了一个效能调控位点,当用碱性基团靶向形成盐桥时,尽管它们暴露于溶剂中,但可将抑制剂亲和力提高多达750倍。构效关系(SAR)和X射线晶体学研究表明,这种效应归因于蛋白质与配体之间的静电相互作用。这种相互作用可被重新利用来创建新的SOS1抑制剂,证明了其在核心探索中的普遍效用。文献中最近的其他例子表明,这种现象可能适用于许多靶点类别,并在此予以强调。

相似文献

1
Exploiting Solvent Exposed Salt-Bridge Interactions for the Discovery of Potent Inhibitors of SOS1 Using Free-Energy Perturbation Simulations.
ACS Med Chem Lett. 2025 Feb 28;16(3):444-453. doi: 10.1021/acsmedchemlett.4c00602. eCollection 2025 Mar 13.
2
Management of urinary stones by experts in stone disease (ESD 2025).
Arch Ital Urol Androl. 2025 Jun 30;97(2):14085. doi: 10.4081/aiua.2025.14085.
3
The Black Book of Psychotropic Dosing and Monitoring.
Psychopharmacol Bull. 2024 Jul 8;54(3):8-59.
4
Systemic treatments for metastatic cutaneous melanoma.
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.
5
Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.
Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204. doi: 10.3310/hta10340.
7
Can a Liquid Biopsy Detect Circulating Tumor DNA With Low-passage Whole-genome Sequencing in Patients With a Sarcoma? A Pilot Evaluation.
Clin Orthop Relat Res. 2025 Jan 1;483(1):39-48. doi: 10.1097/CORR.0000000000003161. Epub 2024 Jun 21.
9
"In a State of Flow": A Qualitative Examination of Autistic Adults' Phenomenological Experiences of Task Immersion.
Autism Adulthood. 2024 Sep 16;6(3):362-373. doi: 10.1089/aut.2023.0032. eCollection 2024 Sep.

本文引用的文献

1
Lead Identification of Novel Naphthyridine Derivatives as Potent SOS1 Inhibitors.
ACS Med Chem Lett. 2024 Jun 3;15(6):958-964. doi: 10.1021/acsmedchemlett.4c00156. eCollection 2024 Jun 13.
5
Direct K-Ras Inhibitors to Treat Cancers: Progress, New Insights, and Approaches to Treat Resistance.
Annu Rev Pharmacol Toxicol. 2024 Jan 23;64:231-253. doi: 10.1146/annurev-pharmtox-022823-113946. Epub 2023 Jul 31.
6
Design of Orally-bioavailable Tetra-cyclic phthalazine SOS1 inhibitors with high selectivity against EGFR.
Bioorg Chem. 2023 Jul;136:106536. doi: 10.1016/j.bioorg.2023.106536. Epub 2023 Apr 10.
7
Design, Synthesis, and Bioevaluation of Pyrido[2,3-]pyrimidin-7-ones as Potent SOS1 Inhibitors.
ACS Med Chem Lett. 2023 Jan 12;14(2):183-190. doi: 10.1021/acsmedchemlett.2c00490. eCollection 2023 Feb 9.
8
Discovery of Orally Bioavailable SOS1 Inhibitors for Suppressing KRAS-Driven Carcinoma.
J Med Chem. 2022 Oct 13;65(19):13158-13171. doi: 10.1021/acs.jmedchem.2c00986. Epub 2022 Sep 29.
10
Discovery of a Novel Class of d-Amino Acid Oxidase Inhibitors Using the Schrödinger Computational Platform.
J Med Chem. 2022 May 12;65(9):6775-6802. doi: 10.1021/acs.jmedchem.2c00118. Epub 2022 Apr 28.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验